Skip to main content

Table 5 Summary of reported results for early parasitological response

From: Efficacy of artemisinin-based combination therapy (ACT) in people living with HIV (PLHIV) diagnosed with uncomplicated Plasmodium falciparum malaria in Africa: a WWARN systematic review

Study ID

Malaria drug

HIV drug

Day

Statistics

PLHIV

HIV-uninfected group

Comparison

P-value

Estimate

N

Estimate

N

Statistics

Estimate (95%CI)

 

7

AL or DP

TS

1

Percentage positive

58.3

 

60.5

 

RR

0.97 (0.72–1.31)

0.84

 

AL or DP

TS

2

Percentage positive

19.4

 

5.0

 

RR

3.87 (1.85–8.12)

 < 0.001

9

AL

EFV or NVP

2

N (%) positive

9 (5.3)

171

     
 

AL

LPV/r

2

N (%) positive

9 (8.4)

107

     
 

AL

EFV or NVP

3

N (%) positive

2 (1.2)

171

     
 

AL

LPV/r

3

N (%) positive

2 (1.9)

105

     

11

AL

EFV or NVP or LPV/r

3

Median (IQR) HL(h)

3.51 (2.98–4.03)

22

2.8 (2.38–3.36)

77

  

0.003

12

AL or SP

None

3

N/A

 

N/A

 

N/A

OR

1.15

0.6

17

AL

EFV

N/A

Median (range) PC50 (h)

5.7 (0.3–25.8)a

57

     
 

AL

EFV

N/A

Median (range) PC90 (h)

13.8 (2.9–32.9)a

57

     

18

DP

EFV

N/A

Median (range) PC50 (h)

4.2 (0.6–40.3)

84

     
 

DP

EFV

N/A

Median (range) PC90 (h)

10.1 (3.2–63.1)

84

     
 

DP

EFV

N/A

Median (range) HL (h)

2.2 (1.2–9.8)

84

     
 

DP

EFV

N/A

N (%) HL > 5.5 h

5 (6.0%)

84

     
 

DP

NVP

N/A

Median (range) PC50 (h)

3.1 (0.2–10.3)

46

     
 

DP

NVP

N/A

Median (range) PC90 (h)

8.2 (2.4–19.7)

46

     
 

DP

NVP

N/A

Median (range) HL (h)

2.1 (1.1–6.8)

46

     
 

DP

NVP

N/A

N (%) HL > 5.5 h

1 (2.2%)

46

     

19b

AL

NVP, EFV

3

N (%) positive

8 (11.8)

68

12 (12.1)

99

  

0.944

  1. AL artemether-lumefantrine, ART antiretroviral therapy, DP dihydroartemisinin-piperaquine; EFV efavirenz, h hour, HL half-life, HR hazard ratio, IQR interquartile range, LPV/r lopinavir/ritonavir, N/A information not available, NVP nevirapine, OR odds ratio, PC parasite clearance, RR relative risk, SP sulfadoxine-pyrimethamine, TS trimethoprim-sulfamethoxazole preventive treatment
  2. aPC50 = 6.0 (0.3–24.4) h and PC90 = 13.1 (2.9–30.9) h in the per protocol population, n = 54
  3. bAt baseline all patients were malaria positive by microscopy, but 78.1% were aparasitaemic by nested-PCR